PIK3CA and neoplasm: Similar results were observed in both PIK3CA‐WT and mutant human CRC cell lines with enhanced HLA‐A,B,C levels on the cell surface after knockdown of GLS (Figure 5D,E) or treatment with CB‐839 (Figure S5A,B, Supporting Information), suggesting that GLS inhibition‐induced tumor antigen presentation is independent of PIK3CA status.